HomeCompareCIFU vs MRK

CIFU vs MRK: Dividend Comparison 2026

CIFU yields 16.86% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIFU wins by $3.4K in total portfolio value
10 years
CIFU
CIFU
● Live price
16.86%
Share price
$11.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60.1K
Annual income
$4,747.32
Full CIFU calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CIFU vs MRK

📍 CIFU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIFUMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIFU + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIFU pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIFU
Annual income on $10K today (after 15% tax)
$1,433.39/yr
After 10yr DRIP, annual income (after tax)
$4,035.22/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $4,293.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIFU + MRK for your $10,000?

CIFU: 50%MRK: 50%
100% MRK50/50100% CIFU
Portfolio after 10yr
$58.5K
Annual income
$7,272.73/yr
Blended yield
12.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CIFU
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIFU buys
0
MRK buys
0
No recent congressional trades found for CIFU or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIFUMRK
Forward yield16.86%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$60.1K$56.8K
Annual income after 10y$4,747.32$9,798.13
Total dividends collected$31.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CIFU vs MRK ($10,000, DRIP)

YearCIFU PortfolioCIFU Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,386$1,686.34$11,206$366.19+$1.2KCIFU
2$15,205$1,952.11$12,650$502.35+$2.6KCIFU
3$18,510$2,239.64$14,407$694.19+$4.1KCIFU
4$22,353$2,547.94$16,585$967.82+$5.8KCIFU
5$26,794$2,875.73$19,342$1,363.89+$7.5KCIFU
6$31,891$3,221.49$22,913$1,947.19+$9.0KCIFU
7$37,706$3,583.49$27,662$2,823.89+$10.0KCIFU
8$44,306$3,959.81$34,159$4,173.35+$10.1KCIFU
9$51,756$4,348.45$43,337$6,308.80+$8.4KCIFU
10$60,126$4,747.32$56,776$9,798.13+$3.4KCIFU

CIFU vs MRK: Complete Analysis 2026

CIFUStock

ETF Opportunities Trust - T-REX 2X Long CIFR Daily Target ETF is an exchange traded fund launched by ETF Opportunities Trust. The fund is managed by Tuttle Capital Management, LLC. It invests in public equity markets. The fund invests directly and through derivatives in stocks of companies operating across financials, financial services and capital markets sectors. It uses derivatives such as swaps and options to create its portfolio. It invests in growth and value stocks of companies across diversified market capitalization. ETF Opportunities Trust - T-REX 2X Long CIFR Daily Target ETF was formed on November 21, 2025 and is domiciled in the United States.

Full CIFU Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CIFU vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIFU vs SCHDCIFU vs JEPICIFU vs OCIFU vs KOCIFU vs MAINCIFU vs JNJCIFU vs ABBVCIFU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.